^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HER2 dimerization inhibitor

    Related drugs:
    10d
    Extracellular Fluid Changes During Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P=N/A, N=111, Completed, Florence Nightingale Hospital, Istanbul | Active, not recruiting --> Completed
    Trial completion
    |
    Perjeta (pertuzumab) • cyclophosphamide
    14d
    A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P3, N=200, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive
    |
    docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    15d
    Opti-HER2: De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=186, Active, not recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)
    16d
    Permissive Cardiotoxicity in HER2-Positive Metastatic Breast Cancer With Moderate Left Ventricular Dysfunction. (PubMed, JACC Case Rep)
    Optimal GDMT supports cardiac recovery in patients with asymptomatic left ventricular dysfunction, allowing for continued HER2 therapy. Integrated cardio-oncology care is essential to balance cancer control with cardiovascular safety.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 mutation • EGFR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    16d
    Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer (clinicaltrials.gov)
    P=N/A, N=80, Completed, Deraya University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • lapatinib • Perjeta (pertuzumab)
    17d
    HCB-ONC002: HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer (2025-521040-37-00)
    P2/3, N=224, Recruiting, Fundacio De Recerca Clinic Barcelona-Institut DInvestigacions Biomediques August Pi I Sunyer
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HR negative
    |
    HER2DX
    |
    carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    17d
    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)
    P2, N=74, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
    22d
    CHERRY-PICK: Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Latin American Cooperative Oncology Group | Recruiting --> Active, not recruiting | Trial completion date: Oct 2031 --> Apr 2032 | Trial primary completion date: Oct 2026 --> Apr 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 negative
    |
    Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    23d
    EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Rutgers, The State University of New Jersey
    New P2 trial • Biomarker assay • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)
    24d
    SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=240, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> Jul 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • HER-2 amplification • BRAF V600
    |
    Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)
    24d
    Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane. (PubMed, NPJ Breast Cancer)
    In conclusion, the HER2DX ERBB2 mRNA score provides independent prognostic information in HER2+ advanced breast cancer treated with THP. The HER2DX metastatic prognostic score further improves prognostic accuracy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    HER2DX
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)